Global Drugs for HIV Market Research Report 2023
HIV/AIDS is one of the most serious chronic diseases and the high prevalence of the disease in almost all parts of the world has resulted in an unprecedented awareness regarding the disease.
According to QYResearch’s new survey, global Drugs for HIV market is projected to reach US$ 45750 million in 2029, increasing from US$ 30600 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for HIV market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Drugs for HIV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
According to QYResearch’s new survey, global Drugs for HIV market is projected to reach US$ 45750 million in 2029, increasing from US$ 30600 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs for HIV market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Drugs for HIV market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- ViiV Healthcare
- Gilead Sciences, Inc
- Merck Sharp & Dohme Corp
- Bristol-Myers Squibb Company
- Janssen Pharmaceuticals, Inc.
- Theratechnologies Inc.
- Viatris Pharmaceuticals Inc.
- Genentech, Inc.
- AbbVie Inc.
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
- Integrase Inhibitors
- Combination HIV Medicines
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for HIV Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Integrase Inhibitors
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Market by Application
1.3.1 Global Drugs for HIV Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Drugs for HIV Market Perspective (2018-2029)
2.2 Drugs for HIV Growth Trends by Region
2.2.1 Global Drugs for HIV Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drugs for HIV Historic Market Size by Region (2018-2023)
2.2.3 Drugs for HIV Forecasted Market Size by Region (2024-2029)
2.3 Drugs for HIV Market Dynamics
2.3.1 Drugs for HIV Industry Trends
2.3.2 Drugs for HIV Market Drivers
2.3.3 Drugs for HIV Market Challenges
2.3.4 Drugs for HIV Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Drugs for HIV Players by Revenue
3.1.1 Global Top Drugs for HIV Players by Revenue (2018-2023)
3.1.2 Global Drugs for HIV Revenue Market Share by Players (2018-2023)
3.2 Global Drugs for HIV Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for HIV Revenue
3.4 Global Drugs for HIV Market Concentration Ratio
3.4.1 Global Drugs for HIV Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for HIV Revenue in 2022
3.5 Drugs for HIV Key Players Head office and Area Served
3.6 Key Players Drugs for HIV Product Solution and Service
3.7 Date of Enter into Drugs for HIV Market
3.8 Mergers & Acquisitions, Expansion Plans
4 DRUGS FOR HIV BREAKDOWN DATA BY TYPE
4.1 Global Drugs for HIV Historic Market Size by Type (2018-2023)
4.2 Global Drugs for HIV Forecasted Market Size by Type (2024-2029)
5 DRUGS FOR HIV BREAKDOWN DATA BY APPLICATION
5.1 Global Drugs for HIV Historic Market Size by Application (2018-2023)
5.2 Global Drugs for HIV Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Drugs for HIV Market Size (2018-2029)
6.2 North America Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Drugs for HIV Market Size by Country (2018-2023)
6.4 North America Drugs for HIV Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Drugs for HIV Market Size (2018-2029)
7.2 Europe Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Drugs for HIV Market Size by Country (2018-2023)
7.4 Europe Drugs for HIV Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Drugs for HIV Market Size (2018-2029)
8.2 Asia-Pacific Drugs for HIV Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Drugs for HIV Market Size by Region (2018-2023)
8.4 Asia-Pacific Drugs for HIV Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Drugs for HIV Market Size (2018-2029)
9.2 Latin America Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Drugs for HIV Market Size by Country (2018-2023)
9.4 Latin America Drugs for HIV Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drugs for HIV Market Size (2018-2029)
10.2 Middle East & Africa Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Drugs for HIV Market Size by Country (2018-2023)
10.4 Middle East & Africa Drugs for HIV Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Detail
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Drugs for HIV Introduction
11.1.4 ViiV Healthcare Revenue in Drugs for HIV Business (2018-2023)
11.1.5 ViiV Healthcare Recent Development
11.2 Gilead Sciences, Inc
11.2.1 Gilead Sciences, Inc Company Detail
11.2.2 Gilead Sciences, Inc Business Overview
11.2.3 Gilead Sciences, Inc Drugs for HIV Introduction
11.2.4 Gilead Sciences, Inc Revenue in Drugs for HIV Business (2018-2023)
11.2.5 Gilead Sciences, Inc Recent Development
11.3 Merck Sharp & Dohme Corp
11.3.1 Merck Sharp & Dohme Corp Company Detail
11.3.2 Merck Sharp & Dohme Corp Business Overview
11.3.3 Merck Sharp & Dohme Corp Drugs for HIV Introduction
11.3.4 Merck Sharp & Dohme Corp Revenue in Drugs for HIV Business (2018-2023)
11.3.5 Merck Sharp & Dohme Corp Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Drugs for HIV Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Drugs for HIV Business (2018-2023)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Janssen Pharmaceuticals, Inc.
11.5.1 Janssen Pharmaceuticals, Inc. Company Detail
11.5.2 Janssen Pharmaceuticals, Inc. Business Overview
11.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Introduction
11.5.4 Janssen Pharmaceuticals, Inc. Revenue in Drugs for HIV Business (2018-2023)
11.5.5 Janssen Pharmaceuticals, Inc. Recent Development
11.6 Theratechnologies Inc.
11.6.1 Theratechnologies Inc. Company Detail
11.6.2 Theratechnologies Inc. Business Overview
11.6.3 Theratechnologies Inc. Drugs for HIV Introduction
11.6.4 Theratechnologies Inc. Revenue in Drugs for HIV Business (2018-2023)
11.6.5 Theratechnologies Inc. Recent Development
11.7 Viatris Pharmaceuticals Inc.
11.7.1 Viatris Pharmaceuticals Inc. Company Detail
11.7.2 Viatris Pharmaceuticals Inc. Business Overview
11.7.3 Viatris Pharmaceuticals Inc. Drugs for HIV Introduction
11.7.4 Viatris Pharmaceuticals Inc. Revenue in Drugs for HIV Business (2018-2023)
11.7.5 Viatris Pharmaceuticals Inc. Recent Development
11.8 Genentech, Inc.
11.8.1 Genentech, Inc. Company Detail
11.8.2 Genentech, Inc. Business Overview
11.8.3 Genentech, Inc. Drugs for HIV Introduction
11.8.4 Genentech, Inc. Revenue in Drugs for HIV Business (2018-2023)
11.8.5 Genentech, Inc. Recent Development
11.9 AbbVie Inc.
11.9.1 AbbVie Inc. Company Detail
11.9.2 AbbVie Inc. Business Overview
11.9.3 AbbVie Inc. Drugs for HIV Introduction
11.9.4 AbbVie Inc. Revenue in Drugs for HIV Business (2018-2023)
11.9.5 AbbVie Inc. Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for HIV Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Integrase Inhibitors
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Market by Application
1.3.1 Global Drugs for HIV Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 GLOBAL GROWTH TRENDS
2.1 Global Drugs for HIV Market Perspective (2018-2029)
2.2 Drugs for HIV Growth Trends by Region
2.2.1 Global Drugs for HIV Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drugs for HIV Historic Market Size by Region (2018-2023)
2.2.3 Drugs for HIV Forecasted Market Size by Region (2024-2029)
2.3 Drugs for HIV Market Dynamics
2.3.1 Drugs for HIV Industry Trends
2.3.2 Drugs for HIV Market Drivers
2.3.3 Drugs for HIV Market Challenges
2.3.4 Drugs for HIV Market Restraints
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Drugs for HIV Players by Revenue
3.1.1 Global Top Drugs for HIV Players by Revenue (2018-2023)
3.1.2 Global Drugs for HIV Revenue Market Share by Players (2018-2023)
3.2 Global Drugs for HIV Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for HIV Revenue
3.4 Global Drugs for HIV Market Concentration Ratio
3.4.1 Global Drugs for HIV Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for HIV Revenue in 2022
3.5 Drugs for HIV Key Players Head office and Area Served
3.6 Key Players Drugs for HIV Product Solution and Service
3.7 Date of Enter into Drugs for HIV Market
3.8 Mergers & Acquisitions, Expansion Plans
4 DRUGS FOR HIV BREAKDOWN DATA BY TYPE
4.1 Global Drugs for HIV Historic Market Size by Type (2018-2023)
4.2 Global Drugs for HIV Forecasted Market Size by Type (2024-2029)
5 DRUGS FOR HIV BREAKDOWN DATA BY APPLICATION
5.1 Global Drugs for HIV Historic Market Size by Application (2018-2023)
5.2 Global Drugs for HIV Forecasted Market Size by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Drugs for HIV Market Size (2018-2029)
6.2 North America Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Drugs for HIV Market Size by Country (2018-2023)
6.4 North America Drugs for HIV Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 EUROPE
7.1 Europe Drugs for HIV Market Size (2018-2029)
7.2 Europe Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Drugs for HIV Market Size by Country (2018-2023)
7.4 Europe Drugs for HIV Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 ASIA-PACIFIC
8.1 Asia-Pacific Drugs for HIV Market Size (2018-2029)
8.2 Asia-Pacific Drugs for HIV Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Drugs for HIV Market Size by Region (2018-2023)
8.4 Asia-Pacific Drugs for HIV Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 LATIN AMERICA
9.1 Latin America Drugs for HIV Market Size (2018-2029)
9.2 Latin America Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Drugs for HIV Market Size by Country (2018-2023)
9.4 Latin America Drugs for HIV Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Drugs for HIV Market Size (2018-2029)
10.2 Middle East & Africa Drugs for HIV Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Drugs for HIV Market Size by Country (2018-2023)
10.4 Middle East & Africa Drugs for HIV Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 KEY PLAYERS PROFILES
11.1 ViiV Healthcare
11.1.1 ViiV Healthcare Company Detail
11.1.2 ViiV Healthcare Business Overview
11.1.3 ViiV Healthcare Drugs for HIV Introduction
11.1.4 ViiV Healthcare Revenue in Drugs for HIV Business (2018-2023)
11.1.5 ViiV Healthcare Recent Development
11.2 Gilead Sciences, Inc
11.2.1 Gilead Sciences, Inc Company Detail
11.2.2 Gilead Sciences, Inc Business Overview
11.2.3 Gilead Sciences, Inc Drugs for HIV Introduction
11.2.4 Gilead Sciences, Inc Revenue in Drugs for HIV Business (2018-2023)
11.2.5 Gilead Sciences, Inc Recent Development
11.3 Merck Sharp & Dohme Corp
11.3.1 Merck Sharp & Dohme Corp Company Detail
11.3.2 Merck Sharp & Dohme Corp Business Overview
11.3.3 Merck Sharp & Dohme Corp Drugs for HIV Introduction
11.3.4 Merck Sharp & Dohme Corp Revenue in Drugs for HIV Business (2018-2023)
11.3.5 Merck Sharp & Dohme Corp Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Detail
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Drugs for HIV Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Drugs for HIV Business (2018-2023)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Janssen Pharmaceuticals, Inc.
11.5.1 Janssen Pharmaceuticals, Inc. Company Detail
11.5.2 Janssen Pharmaceuticals, Inc. Business Overview
11.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Introduction
11.5.4 Janssen Pharmaceuticals, Inc. Revenue in Drugs for HIV Business (2018-2023)
11.5.5 Janssen Pharmaceuticals, Inc. Recent Development
11.6 Theratechnologies Inc.
11.6.1 Theratechnologies Inc. Company Detail
11.6.2 Theratechnologies Inc. Business Overview
11.6.3 Theratechnologies Inc. Drugs for HIV Introduction
11.6.4 Theratechnologies Inc. Revenue in Drugs for HIV Business (2018-2023)
11.6.5 Theratechnologies Inc. Recent Development
11.7 Viatris Pharmaceuticals Inc.
11.7.1 Viatris Pharmaceuticals Inc. Company Detail
11.7.2 Viatris Pharmaceuticals Inc. Business Overview
11.7.3 Viatris Pharmaceuticals Inc. Drugs for HIV Introduction
11.7.4 Viatris Pharmaceuticals Inc. Revenue in Drugs for HIV Business (2018-2023)
11.7.5 Viatris Pharmaceuticals Inc. Recent Development
11.8 Genentech, Inc.
11.8.1 Genentech, Inc. Company Detail
11.8.2 Genentech, Inc. Business Overview
11.8.3 Genentech, Inc. Drugs for HIV Introduction
11.8.4 Genentech, Inc. Revenue in Drugs for HIV Business (2018-2023)
11.8.5 Genentech, Inc. Recent Development
11.9 AbbVie Inc.
11.9.1 AbbVie Inc. Company Detail
11.9.2 AbbVie Inc. Business Overview
11.9.3 AbbVie Inc. Drugs for HIV Introduction
11.9.4 AbbVie Inc. Revenue in Drugs for HIV Business (2018-2023)
11.9.5 AbbVie Inc. Recent Development
12 ANALYST'S VIEWPOINTS/CONCLUSIONS
13 APPENDIX
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
LIST OF TABLES
Table 1. Global Drugs for HIV Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 3. Key Players of Integrase Inhibitors
Table 4. Key Players of Combination HIV Medicines
Table 5. Key Players of Others
Table 6. Global Drugs for HIV Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Drugs for HIV Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Drugs for HIV Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Drugs for HIV Market Share by Region (2018-2023)
Table 10. Global Drugs for HIV Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Drugs for HIV Market Share by Region (2024-2029)
Table 12. Drugs for HIV Market Trends
Table 13. Drugs for HIV Market Drivers
Table 14. Drugs for HIV Market Challenges
Table 15. Drugs for HIV Market Restraints
Table 16. Global Drugs for HIV Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Drugs for HIV Market Share by Players (2018-2023)
Table 18. Global Top Drugs for HIV Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2022)
Table 19. Ranking of Global Top Drugs for HIV Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Drugs for HIV Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Drugs for HIV Product Solution and Service
Table 23. Date of Enter into Drugs for HIV Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Drugs for HIV Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Table 27. Global Drugs for HIV Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Drugs for HIV Revenue Market Share by Type (2024-2029)
Table 29. Global Drugs for HIV Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Drugs for HIV Revenue Market Share by Application (2018-2023)
Table 31. Global Drugs for HIV Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Drugs for HIV Revenue Market Share by Application (2024-2029)
Table 33. North America Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Drugs for HIV Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Drugs for HIV Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Drugs for HIV Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 48. ViiV Healthcare Company Detail
Table 49. ViiV Healthcare Business Overview
Table 50. ViiV Healthcare Drugs for HIV Product
Table 51. ViiV Healthcare Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 52. ViiV Healthcare Recent Development
Table 53. Gilead Sciences, Inc Company Detail
Table 54. Gilead Sciences, Inc Business Overview
Table 55. Gilead Sciences, Inc Drugs for HIV Product
Table 56. Gilead Sciences, Inc Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 57. Gilead Sciences, Inc Recent Development
Table 58. Merck Sharp & Dohme Corp Company Detail
Table 59. Merck Sharp & Dohme Corp Business Overview
Table 60. Merck Sharp & Dohme Corp Drugs for HIV Product
Table 61. Merck Sharp & Dohme Corp Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 62. Merck Sharp & Dohme Corp Recent Development
Table 63. Bristol-Myers Squibb Company Company Detail
Table 64. Bristol-Myers Squibb Company Business Overview
Table 65. Bristol-Myers Squibb Company Drugs for HIV Product
Table 66. Bristol-Myers Squibb Company Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 67. Bristol-Myers Squibb Company Recent Development
Table 68. Janssen Pharmaceuticals, Inc. Company Detail
Table 69. Janssen Pharmaceuticals, Inc. Business Overview
Table 70. Janssen Pharmaceuticals, Inc. Drugs for HIV Product
Table 71. Janssen Pharmaceuticals, Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 72. Janssen Pharmaceuticals, Inc. Recent Development
Table 73. Theratechnologies Inc. Company Detail
Table 74. Theratechnologies Inc. Business Overview
Table 75. Theratechnologies Inc. Drugs for HIV Product
Table 76. Theratechnologies Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 77. Theratechnologies Inc. Recent Development
Table 78. Viatris Pharmaceuticals Inc. Company Detail
Table 79. Viatris Pharmaceuticals Inc. Business Overview
Table 80. Viatris Pharmaceuticals Inc. Drugs for HIV Product
Table 81. Viatris Pharmaceuticals Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 82. Viatris Pharmaceuticals Inc. Recent Development
Table 83. Genentech, Inc. Company Detail
Table 84. Genentech, Inc. Business Overview
Table 85. Genentech, Inc. Drugs for HIV Product
Table 86. Genentech, Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 87. Genentech, Inc. Recent Development
Table 88. AbbVie Inc. Company Detail
Table 89. AbbVie Inc. Business Overview
Table 90. AbbVie Inc. Drugs for HIV Product
Table 91. AbbVie Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 92. AbbVie Inc. Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 1. Global Drugs for HIV Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Table 3. Key Players of Integrase Inhibitors
Table 4. Key Players of Combination HIV Medicines
Table 5. Key Players of Others
Table 6. Global Drugs for HIV Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global Drugs for HIV Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Drugs for HIV Market Size by Region (2018-2023) & (US$ Million)
Table 9. Global Drugs for HIV Market Share by Region (2018-2023)
Table 10. Global Drugs for HIV Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 11. Global Drugs for HIV Market Share by Region (2024-2029)
Table 12. Drugs for HIV Market Trends
Table 13. Drugs for HIV Market Drivers
Table 14. Drugs for HIV Market Challenges
Table 15. Drugs for HIV Market Restraints
Table 16. Global Drugs for HIV Revenue by Players (2018-2023) & (US$ Million)
Table 17. Global Drugs for HIV Market Share by Players (2018-2023)
Table 18. Global Top Drugs for HIV Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2022)
Table 19. Ranking of Global Top Drugs for HIV Companies by Revenue (US$ Million) in 2022
Table 20. Global 5 Largest Players Market Share by Drugs for HIV Revenue (CR5 and HHI) & (2018-2023)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Drugs for HIV Product Solution and Service
Table 23. Date of Enter into Drugs for HIV Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Drugs for HIV Market Size by Type (2018-2023) & (US$ Million)
Table 26. Global Drugs for HIV Revenue Market Share by Type (2018-2023)
Table 27. Global Drugs for HIV Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 28. Global Drugs for HIV Revenue Market Share by Type (2024-2029)
Table 29. Global Drugs for HIV Market Size by Application (2018-2023) & (US$ Million)
Table 30. Global Drugs for HIV Revenue Market Share by Application (2018-2023)
Table 31. Global Drugs for HIV Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 32. Global Drugs for HIV Revenue Market Share by Application (2024-2029)
Table 33. North America Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 34. North America Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 36. Europe Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. Europe Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 38. Europe Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 39. Asia-Pacific Drugs for HIV Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 40. Asia-Pacific Drugs for HIV Market Size by Region (2018-2023) & (US$ Million)
Table 41. Asia-Pacific Drugs for HIV Market Size by Region (2024-2029) & (US$ Million)
Table 42. Latin America Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 43. Latin America Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 44. Latin America Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Drugs for HIV Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Middle East & Africa Drugs for HIV Market Size by Country (2018-2023) & (US$ Million)
Table 47. Middle East & Africa Drugs for HIV Market Size by Country (2024-2029) & (US$ Million)
Table 48. ViiV Healthcare Company Detail
Table 49. ViiV Healthcare Business Overview
Table 50. ViiV Healthcare Drugs for HIV Product
Table 51. ViiV Healthcare Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 52. ViiV Healthcare Recent Development
Table 53. Gilead Sciences, Inc Company Detail
Table 54. Gilead Sciences, Inc Business Overview
Table 55. Gilead Sciences, Inc Drugs for HIV Product
Table 56. Gilead Sciences, Inc Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 57. Gilead Sciences, Inc Recent Development
Table 58. Merck Sharp & Dohme Corp Company Detail
Table 59. Merck Sharp & Dohme Corp Business Overview
Table 60. Merck Sharp & Dohme Corp Drugs for HIV Product
Table 61. Merck Sharp & Dohme Corp Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 62. Merck Sharp & Dohme Corp Recent Development
Table 63. Bristol-Myers Squibb Company Company Detail
Table 64. Bristol-Myers Squibb Company Business Overview
Table 65. Bristol-Myers Squibb Company Drugs for HIV Product
Table 66. Bristol-Myers Squibb Company Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 67. Bristol-Myers Squibb Company Recent Development
Table 68. Janssen Pharmaceuticals, Inc. Company Detail
Table 69. Janssen Pharmaceuticals, Inc. Business Overview
Table 70. Janssen Pharmaceuticals, Inc. Drugs for HIV Product
Table 71. Janssen Pharmaceuticals, Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 72. Janssen Pharmaceuticals, Inc. Recent Development
Table 73. Theratechnologies Inc. Company Detail
Table 74. Theratechnologies Inc. Business Overview
Table 75. Theratechnologies Inc. Drugs for HIV Product
Table 76. Theratechnologies Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 77. Theratechnologies Inc. Recent Development
Table 78. Viatris Pharmaceuticals Inc. Company Detail
Table 79. Viatris Pharmaceuticals Inc. Business Overview
Table 80. Viatris Pharmaceuticals Inc. Drugs for HIV Product
Table 81. Viatris Pharmaceuticals Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 82. Viatris Pharmaceuticals Inc. Recent Development
Table 83. Genentech, Inc. Company Detail
Table 84. Genentech, Inc. Business Overview
Table 85. Genentech, Inc. Drugs for HIV Product
Table 86. Genentech, Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 87. Genentech, Inc. Recent Development
Table 88. AbbVie Inc. Company Detail
Table 89. AbbVie Inc. Business Overview
Table 90. AbbVie Inc. Drugs for HIV Product
Table 91. AbbVie Inc. Revenue in Drugs for HIV Business (2018-2023) & (US$ Million)
Table 92. AbbVie Inc. Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Drugs for HIV Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Drugs for HIV Market Share by Type: 2022 VS 2029
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 4. Integrase Inhibitors Features
Figure 5. Combination HIV Medicines Features
Figure 6. Others Features
Figure 7. Global Drugs for HIV Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Drugs for HIV Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Drugs for HIV Report Years Considered
Figure 14. Global Drugs for HIV Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Drugs for HIV Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Drugs for HIV Market Share by Region: 2022 VS 2029
Figure 17. Global Drugs for HIV Market Share by Players in 2022
Figure 18. Global Top Drugs for HIV Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Drugs for HIV Revenue in 2022
Figure 20. North America Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Drugs for HIV Market Share by Country (2018-2029)
Figure 22. United States Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Drugs for HIV Market Share by Country (2018-2029)
Figure 26. Germany Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Drugs for HIV Market Share by Region (2018-2029)
Figure 34. China Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Drugs for HIV Market Share by Country (2018-2029)
Figure 42. Mexico Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Drugs for HIV Market Share by Country (2018-2029)
Figure 46. Turkey Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. ViiV Healthcare Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 49. Gilead Sciences, Inc Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 50. Merck Sharp & Dohme Corp Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 52. Janssen Pharmaceuticals, Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 53. Theratechnologies Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 54. Viatris Pharmaceuticals Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 55. Genentech, Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 56. AbbVie Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Figure 1. Global Drugs for HIV Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Drugs for HIV Market Share by Type: 2022 VS 2029
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Features
Figure 4. Integrase Inhibitors Features
Figure 5. Combination HIV Medicines Features
Figure 6. Others Features
Figure 7. Global Drugs for HIV Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 8. Global Drugs for HIV Market Share by Application: 2022 VS 2029
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Retail Pharmacies Case Studies
Figure 11. Online Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Drugs for HIV Report Years Considered
Figure 14. Global Drugs for HIV Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Drugs for HIV Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Drugs for HIV Market Share by Region: 2022 VS 2029
Figure 17. Global Drugs for HIV Market Share by Players in 2022
Figure 18. Global Top Drugs for HIV Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for HIV as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Drugs for HIV Revenue in 2022
Figure 20. North America Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Drugs for HIV Market Share by Country (2018-2029)
Figure 22. United States Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Canada Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Drugs for HIV Market Share by Country (2018-2029)
Figure 26. Germany Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. France Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. U.K. Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Italy Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Russia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Nordic Countries Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Drugs for HIV Market Share by Region (2018-2029)
Figure 34. China Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Japan Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. South Korea Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Southeast Asia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. India Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Australia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Drugs for HIV Market Share by Country (2018-2029)
Figure 42. Mexico Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Brazil Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Drugs for HIV Market Share by Country (2018-2029)
Figure 46. Turkey Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Saudi Arabia Drugs for HIV Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. ViiV Healthcare Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 49. Gilead Sciences, Inc Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 50. Merck Sharp & Dohme Corp Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 52. Janssen Pharmaceuticals, Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 53. Theratechnologies Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 54. Viatris Pharmaceuticals Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 55. Genentech, Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 56. AbbVie Inc. Revenue Growth Rate in Drugs for HIV Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
